A Phase 2 interventional study of MEBO Wound Ointment (MEBO) and Standard of Care in Ulcers, sponsored by Skingenix, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-06.
Sponsored by Skingenix, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 141 studies in Ulcer with a site in United States — 24 open to participants now, 27 under way, none of them phase 3. Ulcer · United States.
Among the 141 studies in Ulcer with a site in United States, this one is the 117th largest by enrollment of the 124 interventional ones that give a count, is one of 5 that started in 2010, is one of 29 in phase 2, and was the 44th registered.
360 studies on the registry are indexed under Ulcer; 61 are open to participants now.
Browse Ulcer studies →24 of the 141 studies in Ulcer with a site in United States are open now. Recruiting first, the newest first:
UNCANCER LLC · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, Canada and 7 more countries
Ages 2–11
Athos Therapeutics Inc · Sites in United States
Ages 18–75
Sequence LifeScience, Inc. · Sites in United States
Ages 18+
BioLab Holdings · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Ulcer studies recruiting now, 30 (77%) set no upper age limit and 3 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
141 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 32 · Phase 3 18 · Phase 4 10
First in 1994; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 65 across 292 interventional studies indexed under Ulcer.
Median enrollment 95 across the 124 interventional studies, 87 across the 16 observational. Of the 97 that completed or were terminated, 43 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
95 of 141 have an industry lead sponsor. The 10 most frequent:
Skingenix, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Skingenix, Inc. has 1 study filed under Ulcer — fewer than ten, so there is no comparison to draw.
13 of the studies in Ulcer with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06674980C5 BiomedicalClinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs | 2026-11-22 |
| NCT05739149Mayo ClinicA Study to Evaluate Microvessel Ultrasound Imaging of Wound Healing in Patients With Chronic Ulcers | 2026-12-10 |
| NCT07364630BioLab HoldingsEfficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers | 2027-01 |
| NCT06616844ConvaTec Inc.IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers | 2027-03 |
| NCT06742801Medtronic EndovascularOnyx™ Liquid Embolic IDE Clinical Study | 2027-04 |
Add all 13 to your calendar (.ics) → With an account.
Among the 141 studies in Ulcer with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase II, randomized, controlled, two-center pilot study designed to assess the safety and efficacy of MEBO in the treatment of 14 subjects with VLUs. Subjects meeting entry criteria will be randomly assigned in a 1:1 ratio for up to 8 weeks of treatment with either MEBO or SOC (7 subjects per treatment arm).
To assess the safety and efficacy of MEBO in the treatment of 14 subjects with VLUs. Subjects meeting entry criteria will be randomly assigned in a 1:1 ratio for up to 8 weeks of treatment with either MEBO or SOC (7 subjects per treatment arm).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical application once a day
Drug: MEBO Wound Ointment (MEBO)
Application of Profore multilayer compression bandage system
Procedure: Standard of Care
Topical application once a day
Also known as: MEBO
Application of Profore multilayer compression bandage system
Incidence of complete healing of the target ulcer within the 8-week treatment period.
Time frame: 8 week treatment period
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Nov 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Skingenix, Inc.